Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2

Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2

Targeted inhibition of Bruton’s Tyrosine Kinase (BTK) with ibrutinib and other agents has become important treatment options in chronic lymphocytic leukemia, Waldenström’s Macroglobulinemia, Mantle cell lymphoma, and non-GCB DLBCL. Clinical trials combining small molecule inhibitors with monoclonal...

Full description

Bibliographic Details
Main Authors: Verena Barbarino, Sinika Henschke, Stuart James Blakemore, Elena Izquierdo, Michael Michalik, Nadine Nickel, Indra Möllenkotte, Daniela Vorholt, Linda Müller, Reinhild Brinker, Oleg Fedorchenko, Nelly Mikhael, Tamina Seeger-Nukpezah, Michael Hallek, Christian P. Pallasch
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Cancers
Subjects:
Ibrutinib
JAK
ruxolitinib
B-cell lymphoma
macrophage
phagocytosis
Online Access:https://www.mdpi.com/2072-6694/12/8/2303

Internet

https://www.mdpi.com/2072-6694/12/8/2303

Similar Items